Suppr超能文献

新型靶向乙酰胆碱酯酶和σ受体的多靶点配体作为治疗阿尔茨海默病的先导化合物:与乙酰胆碱酯酶形成复合物的合成、评价和结构特征。

Novel multitarget-directed ligands targeting acetylcholinesterase and σ receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase.

机构信息

Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie Univ, UNICAEN, CERMN, 14000, Caen, France.

Univ Grenoble Alpes, IBS, F-38027, Grenoble, France; CNRS, IBS, F-38027, Grenoble, France; CEA, IBS, F-38027, Grenoble, France.

出版信息

Eur J Med Chem. 2019 Jan 15;162:234-248. doi: 10.1016/j.ejmech.2018.10.064. Epub 2018 Nov 8.

Abstract

Pleiotropic intervention may be a requirement for effective limitation of the progression of multifactorial diseases such as Alzheimer's Disease. One approach to such intervention is to design a single chemical entity capable of acting on two or more targets of interest, which are accordingly known as Multi-Target Directed Ligands (MTDLs). We recently described donecopride, the first MTDL able to simultaneously inhibit acetylcholinesterase and act as an agonist of the 5-HT receptor, which displays promising activities in vivo. Pharmacomodulation of donecopride allowed us to develop a novel series of indole derivatives possessing interesting in vitro activities toward AChE and the σ receptor. The crystal structures of complexes of the most promising compounds with Torpedo californica AChE were solved in order to further understand their mode of inhibition.

摘要

多效干预可能是有效限制阿尔茨海默病等多因素疾病进展的必要条件。这种干预的一种方法是设计一种能够同时作用于两个或多个感兴趣的靶标的单一化学实体,因此被称为多靶点定向配体(MTDL)。我们最近描述了多奈哌齐,它是第一个能够同时抑制乙酰胆碱酯酶并作为 5-HT 受体激动剂的 MTDL,在体内显示出有希望的活性。多奈哌齐的药物修饰使我们能够开发出一系列新型吲哚衍生物,这些衍生物对 AChE 和 σ 受体具有有趣的体外活性。为了进一步了解它们的抑制模式,我们解决了与加利福尼亚虎斑乌贼 AChE 结合的最有前途的化合物的复合物的晶体结构。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验